Effective therapy for chronic spontaneous urticaria may lower mortality: Study

The electronic medical data of 1,27,28,913 non-urticaria controls and 2,72,190 adult CSU patients from the US Collaborative TriNetx Analytics Network are the subjects of this retrospective population-based cohort research. A total of 2,64,680 propensity score-matched people suffering from CSU and an equal number of non-urticaria controls were included in the research.

The patients with CSU had greater 3-month, 1-year, and 5-year all-cause mortality. CSU patients had greater risk and incidence of the top causes of mortality in the US, such as malignant neoplasms and suicidal thoughts and attempts, than non-CSU controls.

White and younger patients seemed to be at a higher risk of death at CSU. When compared to patients who were not treated, CSU patients treated with second-generation H1-antihistamines had significantly reduced all-cause death rates at 5 years, as were patients treated with omalizumab as opposed to those treated with antihistamines.

Overall, chronic spontaneous urticaria patients had a 1.7-fold higher risk of all-cause death than the individuals without CSU. Mortality rates were reduced by CSU therapy with omalizumab and second-generation antihistamines by indicating that these risks might be reduced with appropriate care.

Source:

Kolkhir, P., Bieber, K., Hawro, T., Kridin, K., Ludwig, M. A., Olbrich, H., Metz, M., Vorobyev, A., Ludwig, R. J., & Maurer, M. (2024). Mortality in adult patients with chronic spontaneous urticaria: A real world cohort study. In Journal of Allergy and Clinical Immunology. Elsevier BV. https://doi.org/10.1016/j.jaci.2024.11.036